HRP20191175T1 - Spojevi koji su inhibitori signaliziranja u notch putu - Google Patents
Spojevi koji su inhibitori signaliziranja u notch putu Download PDFInfo
- Publication number
- HRP20191175T1 HRP20191175T1 HRP20191175TT HRP20191175T HRP20191175T1 HR P20191175 T1 HRP20191175 T1 HR P20191175T1 HR P20191175T T HRP20191175T T HR P20191175TT HR P20191175 T HRP20191175 T HR P20191175T HR P20191175 T1 HRP20191175 T1 HR P20191175T1
- Authority
- HR
- Croatia
- Prior art keywords
- pharmaceutically acceptable
- cancer
- acceptable salt
- diastereomer
- intended
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Claims (8)
1. Spoj, naznačen time što ima strukturu:
,
4,4,4-trifluor-N-((2S)-1-((9-metoksi-3,3-dimetil-5-okso-2,3,5,6-tetrahidro-1H-benzo[f]pirolo[1,2-a]azepin-6-il)amino)-1-oksopropan-2-il)butanamid, njegov dijastereomerni izomer izomerne čistoće na položaju 6 veće od 90% enantiomernog viška, ili farmaceutski prihvatljiva sol bilo kojeg od gore navedenog.
2. Spoj, naznačen time što ima strukturu:
,
N-((2S)-1-((8,8-dimetil-6-okso-6,8,9,10-tetrahidro-5H-pirido[3,2-f]pirolo[1,2-a]azepin-5-il)amino)-1-oksopropan-2-il)-4,4,4-trifluorbutanamid, njegov dijastereomerni izomer izomerne čistoće na položaju 5 veće od 90% enantiomernog viška, ili farmaceutski prihvatljiva sol bilo kojeg od gore navedenog.
3. Farmaceutski pripravak, naznačen time što sadrži bilo spoj u skladu s patentnim zahtjevom 1 ili 2, ili njegov dijastereomer, u skladu s patentnim zahtjevima 1 ili 2, ili njegovu farmaceutski prihvatljivu sol, kao i farmaceutski prihvatljivu podlogu.
4. Spoj u skladu s patentnim zahtjevom 1 ili 2, ili njegov dijastereomer, u skladu s patentnim zahtjevima 1 ili 2, ili njegova farmaceutski prihvatljiva sol, naznačen time što je namijenjen upotrebi u terapiji.
5. Spoj u skladu s patentnim zahtjevom 1 ili 2, ili njegov dijastereomer, u skladu s patentnim zahtjevima 1 ili 2, ili njegova farmaceutski prihvatljiva sol, naznačen time što je namijenjen upotrebi u liječenju akutne limfoblastične leukemije T-stanica, akutne limfoblastične leukemije, kronične limfoblastične leukemije, akutne mijelogene leukemije, kronične mijelogene leukemije, eritroleukemije, trostruko negativnog raka dojke, raka dojke, raka jajnika, melanoma, raka pluća, raka velikih stanica pluća, raka gušterače, glioblastoma, kolorektalnog rak, raka glave i vrata, raka vrata maternice, raka prostate, raka jetre, oral karcinoma pločastih stanica, raka kože, meduloblastoma, angiosarkoma, rabdomiosarkoma, liposarkoma, zloćudnog fibroznog histiocitoma, hepatocelularnog karcinoma, intrahepatičnog ili ekstrahepatičnog kolangiokarcinoma ili adenoidnog cističnog karcinoma.
6. Spoj u skladu s patentnim zahtjevom 1 ili 2, ili njegov dijastereomer, u skladu s patentnim zahtjevima 1 ili 2, ili njegova farmaceutski prihvatljiva sol, naznačen time što je namijenjen upotrebi u skladu s patentnim zahtjevom 5 u liječenju raka pluća.
7. Spoj u skladu s patentnim zahtjevom 1 ili 2, ili njegov dijastereomer, u skladu s patentnim zahtjevima 1 ili 2, ili njegova farmaceutski prihvatljiva sol, naznačen time što je namijenjen upotrebi u liječenju senzorineuralnog gubitka sluha uzrokovanog gubitkom slušnih vlasastih stanica.
8. Spoj u skladu s patentnim zahtjevom 1 ili 2, ili njegov dijastereomer, u skladu s patentnim zahtjevima 1 ili 2, ili njegova farmaceutski prihvatljiva sol, naznačen time što je namijenjen upotrebi u induciranju generiranja slušnih vlasastih stanica.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562189393P | 2015-07-07 | 2015-07-07 | |
| PCT/US2016/040612 WO2017007702A1 (en) | 2015-07-07 | 2016-07-01 | Notch pathway signaling inhibitor compounds |
| EP16741742.7A EP3319967B1 (en) | 2015-07-07 | 2016-07-01 | Notch pathway signaling inhibitor compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20191175T1 true HRP20191175T1 (hr) | 2019-10-04 |
Family
ID=56507825
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20191175TT HRP20191175T1 (hr) | 2015-07-07 | 2019-06-28 | Spojevi koji su inhibitori signaliziranja u notch putu |
Country Status (42)
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20150209367A1 (en) | 2012-09-07 | 2015-07-30 | Massachusetts Eye & Ear Infirmary | Treating Hearing Loss |
| AR105080A1 (es) | 2015-07-07 | 2017-09-06 | Lilly Co Eli | Compuestos inhibidores de la señalización de la vía de notch |
| CA3029281A1 (en) | 2016-06-29 | 2018-01-04 | Otonomy, Inc. | Triglyceride otic formulations and uses thereof |
| US11253193B2 (en) * | 2016-11-08 | 2022-02-22 | Cochlear Limited | Utilization of vocal acoustic biomarkers for assistive listening device utilization |
| KR20190098998A (ko) | 2016-12-16 | 2019-08-23 | 파이프라인 테라퓨틱스, 아이엔씨. | 달팽이관 시냅스질환의 치료 방법 |
| TW201838989A (zh) * | 2017-03-24 | 2018-11-01 | 瑞士商諾華公司 | 異噁唑羧醯胺化合物及其用途 |
| US11117932B2 (en) * | 2018-07-20 | 2021-09-14 | The Hong Kong Polytechnic University | Peptides for specific inhibition of Jag 1-Notch 1 pathway |
| CR20210148A (es) * | 2018-09-21 | 2021-05-18 | Novartis Ag | Compuestos de isoxazol carboxamida y usos de los mismos |
| WO2020072602A1 (en) | 2018-10-02 | 2020-04-09 | Frequency Therapeutics, Inc. | Pharmaceutical compositions comprising otic therapeutic agents and related methods |
| WO2020112883A1 (en) * | 2018-11-30 | 2020-06-04 | Massachusetts Eye And Ear Infirmary | Inhibition of lysine demethylase 1 (lsd1) induces differentiation of hair cells |
| CA3136424A1 (en) | 2019-04-08 | 2020-10-15 | Frequency Therapeutics, Inc. | Combination of chir99021 and valproic acid for treating hearing loss |
| WO2021150672A2 (en) * | 2020-01-22 | 2021-07-29 | Beth Israel Deaconess Medical Center, Inc. | Biomarkers for placenta accreta spectrum (pas) disorders |
| WO2022158610A1 (en) * | 2021-01-20 | 2022-07-28 | Prism BioLab Co., Ltd. | Novel bicyclic compounds |
| WO2023200017A1 (en) * | 2022-04-11 | 2023-10-19 | Prism BioLab Co., Ltd. | Novel seven-membered ring-fused compounds |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8673634B2 (en) | 2003-11-13 | 2014-03-18 | Massachusetts Eye & Ear Infirmary | Method for the treatment of hearing loss |
| MX2008012136A (es) | 2006-03-27 | 2008-10-03 | Hoffmann La Roche | Derivados de malonamida como inhibidores de gama secretasa. |
| EP2732819B1 (en) | 2008-02-07 | 2019-10-16 | Massachusetts Eye & Ear Infirmary | Compounds that enhance Atoh-1 expression |
| US8648119B2 (en) | 2008-05-23 | 2014-02-11 | Otonomy, Inc. | Controlled release immunomodulator compositions and methods for the treatment of otic disorders |
| AU2009316264B2 (en) | 2008-11-24 | 2016-09-15 | Massachusetts Eye & Ear Infirmary | Pathways to generate hair cells |
| WO2012047706A2 (en) | 2010-10-06 | 2012-04-12 | Massachusetts Eye & Ear Infirmary | Methods for promotiing reinnervation of auditory hair cells |
| AR087107A1 (es) * | 2011-07-27 | 2014-02-12 | Lilly Co Eli | Compuesto inhibidor de la señalizacion de la trayectoria notch |
| US8716229B2 (en) | 2011-11-09 | 2014-05-06 | Massachusetts Eye & Ear Infirmary | Osteoprotegerin in neuroprotection |
| US20150209367A1 (en) * | 2012-09-07 | 2015-07-30 | Massachusetts Eye & Ear Infirmary | Treating Hearing Loss |
| EP2914724A1 (en) | 2012-11-02 | 2015-09-09 | Genesys Research Institute | Compositions and methods for auditory therapy |
| AR105080A1 (es) | 2015-07-07 | 2017-09-06 | Lilly Co Eli | Compuestos inhibidores de la señalización de la vía de notch |
| KR20190098998A (ko) * | 2016-12-16 | 2019-08-23 | 파이프라인 테라퓨틱스, 아이엔씨. | 달팽이관 시냅스질환의 치료 방법 |
-
2016
- 2016-06-21 AR ARP160101848A patent/AR105080A1/es active IP Right Grant
- 2016-06-21 TW TW105119456A patent/TWI625332B/zh active
- 2016-06-21 JO JOP/2016/0125A patent/JO3491B1/ar active
- 2016-07-01 AU AU2016289822A patent/AU2016289822B2/en active Active
- 2016-07-01 WO PCT/US2016/040612 patent/WO2017007702A1/en active Application Filing
- 2016-07-01 TN TNP/2017/000495A patent/TN2017000495A1/en unknown
- 2016-07-01 TR TR2019/08683T patent/TR201908683T4/tr unknown
- 2016-07-01 MX MX2017016555A patent/MX376082B/es active IP Right Grant
- 2016-07-01 ME MEP-2019-191A patent/ME03495B/me unknown
- 2016-07-01 MA MA42399A patent/MA42399B1/fr unknown
- 2016-07-01 MY MYPI2018700032A patent/MY197519A/en unknown
- 2016-07-01 LT LTEP16741742.7T patent/LT3319967T/lt unknown
- 2016-07-01 DK DK16741742.7T patent/DK3319967T3/da active
- 2016-07-01 US US15/736,345 patent/US10450317B2/en active Active
- 2016-07-01 UA UAA201712094A patent/UA120539C2/uk unknown
- 2016-07-01 PE PE2018000012A patent/PE20180412A1/es unknown
- 2016-07-01 CR CR20220368A patent/CR20220368A/es unknown
- 2016-07-01 ES ES16741742T patent/ES2735139T3/es active Active
- 2016-07-01 EA EA201792478A patent/EA032634B1/ru not_active IP Right Cessation
- 2016-07-01 JP JP2017568395A patent/JP6571214B2/ja active Active
- 2016-07-01 HU HUE16741742 patent/HUE044666T2/hu unknown
- 2016-07-01 CR CR20170598A patent/CR20170598A/es unknown
- 2016-07-01 PT PT16741742T patent/PT3319967T/pt unknown
- 2016-07-01 CN CN201680039699.XA patent/CN107849054B/zh active Active
- 2016-07-01 CA CA2987431A patent/CA2987431C/en active Active
- 2016-07-01 PL PL16741742T patent/PL3319967T3/pl unknown
- 2016-07-01 KR KR1020187000149A patent/KR102078946B1/ko active Active
- 2016-07-01 SI SI201630270T patent/SI3319967T1/sl unknown
- 2016-07-01 RS RS20190820A patent/RS59115B1/sr unknown
- 2016-07-01 EP EP16741742.7A patent/EP3319967B1/en active Active
- 2016-07-01 MD MDE20180506 patent/MD3319967T2/ro unknown
- 2016-07-01 NZ NZ737322A patent/NZ737322A/en unknown
-
2017
- 2017-11-16 IL IL255726A patent/IL255726B/en active IP Right Grant
- 2017-11-20 ZA ZA2017/07858A patent/ZA201707858B/en unknown
- 2017-12-20 SV SV2017005597A patent/SV2017005597A/es unknown
-
2018
- 2018-01-02 EC ECIEPI201842A patent/ECSP18000042A/es unknown
- 2018-01-02 CL CL2018000007A patent/CL2018000007A1/es unknown
- 2018-01-05 PH PH12018500047A patent/PH12018500047B1/en unknown
- 2018-01-05 DO DO2018000005A patent/DOP2018000005A/es unknown
- 2018-01-12 CO CONC2018/0000224A patent/CO2018000224A2/es unknown
- 2018-05-17 HK HK18106380.5A patent/HK1247187B/zh unknown
-
2019
- 2019-06-28 HR HRP20191175TT patent/HRP20191175T1/hr unknown
- 2019-07-23 CY CY20191100776T patent/CY1122024T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20191175T1 (hr) | Spojevi koji su inhibitori signaliziranja u notch putu | |
| PH12020500066A1 (en) | Carboxamides as modulators of sodium channels | |
| MX2021000781A (es) | Profarmacos de amidas de piridona utiles como moduladores de canales de sodio. | |
| HRP20250119T1 (hr) | Kdm1a inhibitor i njegova primjena u terapiji | |
| MY192084A (en) | Pyrazolo-heteroaryl derivative, preparation method and medical use thereof | |
| PH12015501661A1 (en) | Pyridone amides as modulators of sodium channels | |
| SG10201810985XA (en) | Tofacitinib oral sustained release dosage forms | |
| MX2015009591A (es) | Amidas como moduladores de canales de sodio. | |
| EA201591291A1 (ru) | Производные пиримидона и их применение в лечении, облегчении или профилактике вирусного заболевания | |
| PH12017501811A1 (en) | Compositions containing ibrutinib | |
| NZ756231A (en) | A novel isoindoline derivative, a pharmaceutical composition and use thereof | |
| PH12015500460A1 (en) | Coated pharmaceutical composition containing regorafenib | |
| MX2016000038A (es) | Amidas de piperidina fusionadas como moduladores de canales de iones. | |
| MX2015008288A (es) | Derivados de piridona y su uso en el tratamiento, mejora o prevencion de una enfermedad viral. | |
| EA201400064A1 (ru) | Офтальмологическая фармацевтическая композиция для местного применения, которая содержит регорафениб | |
| IL312732A (en) | Ionizable cationic lipids for rna delivery | |
| WO2015009731A3 (en) | Azacyclic constrained analogs of fty720 | |
| MX2015008292A (es) | Derivados de naftiridinona y su uso en el tratamiento, mejora o prevencion de una enfermedad viral. | |
| MX2021007142A (es) | Compuestos organicos. | |
| MX2009008039A (es) | Gamma lactamas substituidas como agentes terapeuticos. | |
| GR1008228B (el) | Φαρμακευτικο σκευασμα περιεχον ενα διπλο αναστολεα επαναπροσληψης και μεθοδος για την παρασκευη αυτου | |
| MY189372A (en) | Indole derivatives | |
| WO2012153347A3 (en) | Oral pharmaceutical composition of olanzapine form 1 and sodium starch glycolate | |
| HRP20230105T1 (hr) | N,n-bis-2-merkaptoetil izoftalamid za liječenje neurodegenerativnih bolesti | |
| SG11201810308TA (en) | Oral tipepidine preparation |